Abstracts tagged "Lupus nephritis"

Abstract Number: 2851 • 2018 ACR/ARHP Annual Meeting
NF-Κappa b Signaling in the Myeloid Cell Lineage Drives the Pathogenesis of Immune-Mediated Nephritis
Samantha Chalmers¹, Sayra Garcia¹, Justine Shum¹, Leal Herlitz² and Chaim Putterman³, ¹Albert Einstein College of Medicine, Bronx, NY, ²Cleveland Clinic, Cleveland, OH, ³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: Immune-mediated glomerulonephritis is a serious end organ pathology that commonly affects patients with systemic lupus erythematosus (SLE). Nephrotoxic serum nephritis, induced by passive transfer…
Abstract Number: 94 • 2018 ACR/ARHP Annual Meeting
Circulating Soluble MICA Is Associated to Lupus Nephritis and to a TLR/IFN-I Signature in T Cells in a Cohort of Adult SLE Patients
Maria Perez-Ferro¹, Fredeswinda I. Romero-Bueno¹, Cristina Serrano del Castillo², Raquel Largo³, Gabriel Herrero-Beaumont³ and Olga Sanchez-Pernaute⁴, ¹Section for Autoimmune Diseases, Rheumatology, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, ²Immunology, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, ³Bone and Joint Research Unit, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, ⁴Rheumatology Division. Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
Background/Purpose: The MHC class I-related chain A (MICA) is a major ligand for the NKG2D receptor of NK and CD8 T cells. MICA expression at…
Abstract Number: 2893 • 2018 ACR/ARHP Annual Meeting
Clinical Outcomes and Response to Anti-Thrombotic Treatment Among Patients with Concomitant Lupus Nephritis and Thrombotic Microangiopathy: A Multicenter Cohort Study
Savino Sciascia¹, Jinoos Yazdany², Maria Jose Cuadrado³, Massimo Radin⁴, Maria Dall'Era², Ishita Aggarwal⁵, Roberta Fenoglio⁶, Antonella Barreca⁷, Mauro Papotti⁷, Irene Cecchi⁸, Elena Rubini⁹, Karen Schreiber¹⁰ and Dario Roccatello⁶, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ²University of California, San Francisco, San Francisco, CA, ³Clinica Universidad de Navarra, Madrid, Spain, ⁴Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁵Medicine, Santa Clara Valley Medical Center, San Jose, CA, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁷University of Turin, Turin, Italy, ⁸Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ¹⁰Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom., London, United Kingdom
Background/Purpose: Renal vascular involvement is an important prognostic marker of lupus nephritis (LN). Among patients with various vascular changes, individuals with thromboticmicroangiopathy (TMA) present with…
Abstract Number: 95 • 2018 ACR/ARHP Annual Meeting
Expression of SLAMF6 and Its Functional Significance in Podocytes of Lupus Nephritis
Takashi Igawa¹, Kunihiro Ichinose¹, Masataka Umeda¹, Tomohiro Koga¹, Mizuna Eguchi², Momoko Okamoto², Yushiro Endo², Sousuke Tsuji², Ayuko Takatani¹, Toshimasa Shimizu¹, Shoichi Fukui¹, Remi Sumiyoshi², Shinya Kawashiri², Naoki Iwamoto¹, Mami Tamai¹, Hideki Nakamura¹, Tomoki Origuchi³, George C Tsokos⁴ and Atsushi Kawakami¹, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Department of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁴Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus(SLE) is multisystem disorder that is caused by tissue damage resulting from antibody and complement-fixing immune complex deposition. Lupus nephritis(LN) is frequent…
Abstract Number: 2958 • 2018 ACR/ARHP Annual Meeting
Multi-Site Study Evaluating Performance on Lupus Nephritis Quality Measures
Ishita Aggarwal¹, Laura Trupin², Jing Li³, Lisa Gaynon⁴, Nancy Liu⁵, Chris Schlechter⁶, Louise Murphy⁷, Maria Dall'Era⁶ and Jinoos Yazdany⁶, ¹University of California San Francisco, San Francisco, CA, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ³Medicine, UC San Francisco, San Francisco, CA, ⁴Internal Medicine, California Pacific Medical Center, San Francisco, CA, ⁵Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁶University of California, San Francisco, San Francisco, CA, ⁷Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: Lupus nephritis (LN), seen in up to 60% of individuals with SLE, progresses to end stage renal failure in 10-30% of patients within 15…
Abstract Number: 461 • 2018 ACR/ARHP Annual Meeting
Ofatumumab Use in Childhood-Onset Systemic Lupus Erythematosus: A Single-Center Experience
Anna Carmela Sagcal-Gironella¹, Eyal Muscal², Andrea A. Ramirez¹, Monica Marcus³, Miriah Gillispie¹, William Blaine Lapin¹ and Marietta M. De Guzman⁴, ¹Department of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Department of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston, TX, ³Deaprtment of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁴Pediatric Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Ofatumumab is a fully human anti-CD20 monoclonal antibody that has been approved for the treatment of chronic lymphocytic leukemia. It has been increasingly used…
Abstract Number: 464 • 2018 ACR/ARHP Annual Meeting
The Long Term Outcomes in Chinese Children Diagnosed with Systemic Lupus Erythematosus and Biopsy Proven Lupus Nephritis – a 18-Year Cohort
Grace Chiang^1,2, Sik Nin Wong³, Clara Law⁴, Kwok Piu Lee⁵, Cheuk Chun Szeto⁶, Chi Chiu Mok⁷, Lai-Shan Tam⁸ and Ting Fan Leung⁹, ¹Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Sha Tin, Hong Kong, ²Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³Paediatrics and Adolescent Medicine, Tune Mun Hospital, Hong Kong, Hong Kong, ⁴Medicine and Therapeutics, Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hong Kong, ⁵Paediatrics and Adolescent Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong, ⁶Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁷Medicine and Geriatrics, Tune Mun Hospital, Hong Kong, Hong Kong, Hong Kong, ⁸Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, Hong Kong, ⁹Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Renal disease occurs in 50-70% of all childhood onset systemic lupus erythematosus (cSLE). The prevalence of LN is higher in children and the manifestations…
Abstract Number: 665 • 2017 ACR/ARHP Annual Meeting
Low Vitamin D Is Associated with End Stage Renal Disease in Systemic Lupus Erythematosus
Michelle Petri¹, Wei Fu² and Daniel Goldman², ¹Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Vitamin D insufficiency/deficiency is common in SLE. Replacement therapy may help renal disease activity. We asked whether low vitamin D predicted later organ damage.…
Abstract Number: 668 • 2017 ACR/ARHP Annual Meeting
Is Uric Acid Level a Predictor of Long-Term Renal Outcome in Lupus Nephritis?
Michelle Lopes¹, Samara Gavinier², Elaine Leon², Vilma Viana², Eduardo Ferreira Borba¹ and Eloisa Bonfa³, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, São Paulo, Brazil, ³Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Hyperuricemia has been reported to be associated with chronic kidney disease (CKD) in several clinical conditions, and recent studies also observed an association between…
Abstract Number: 671 • 2017 ACR/ARHP Annual Meeting
A New Histological Index for Predicting a Decline in Kidney Function in Patients with Lupus Nephritis. a Mexican Cohort Study of 186 Patients with a Kidney Biopsy
Marco Ulises Martinez-Martinez¹, Cesar Eduardo Vallín Orozco², David Martínez-Galla³ and Carlos Abud-Mendoza⁴, ¹Unidad de Investigaciones Reumatológicas, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico, ²Rheumatology, Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, ³Pathology, Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, ⁴Unidad de Investigaciones Reumatológicas y Osteoporosis, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico
- Background/Purpose: The NIH indexes (of activity and chronicity) were proposed by Austin et al., in 1984. At the moment, there are therapies which can…
Abstract Number: 672 • 2017 ACR/ARHP Annual Meeting
Baseline Hyperuricemia As a Predictive Value for Development of Lupus Nephritis in Premenopausal SLE Patients
Doo-Ho Lim¹, Seokchan Hong², Ji Seon Oh³, Yong-Gil Kim², Chang Keun Lee², Seung Won Choi¹ and Bin Yoo², ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, National Medical Center, Seoul, Korea, Republic of (South)
Background/Purpose: Although lupus nephritis is a common and serious manifestation of SLE, there have been few predictive markers for development of lupus nephritis in SLE…
Abstract Number: 702 • 2017 ACR/ARHP Annual Meeting
Positive Direct Coombs’ Test in the Absence of Hemolytic Anemia Predicts High Disease Activity and Poor Renal Response in Systemic Lupus Erythematosus
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Direct Coombs' test in the absence of hemolytic anemia was newly included in the immunologic criterion of the SLICC/ACR 2012 criteria for SLE. Since…
Abstract Number: 1843 • 2017 ACR/ARHP Annual Meeting
Serum Albumin at 12 Months Post Biopsy Has Excellent Sensitivity and Specificity for Favorable 4 Year Renal Outcome in Lupus Nephritis (LN)
Vinicius Domingues¹, Nicole Bornkamp¹, Benjamin A. Levinson², Judith D. Goldberg², Jill P. Buyon¹ and H. Michael Belmont¹, ¹Medicine, New York University School of Medicine, New York, NY, ²Population Health, New York University School of Medicine, New York, NY
Background/Purpose: LN is a common, deleterious manifestation of systemic lupus erythematosus (SLE) and despite recent advances in treatment remains the most significant end organ injury…
Abstract Number: 1920 • 2017 ACR/ARHP Annual Meeting
Tacrolimus Induces Remission in Refractory and Relapsing Lupus Nephritis By Decreasing P-Glycoprotein Expression and Function on Peripheral Blood Lymphocytes
Vikas Gupta, Sukesh Edavalath, Mohit Kumar Rai, Harshit Singh, Saurabh Chaturvedi and Vikas Agarwal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: About 15-30% of Lupus Nephritis (LN) patients do not respond to first-line immunosuppressive therapy. P-glycoprotein (P-gp) mediated efflux of corticosteroids (CS) may contribute to…
Abstract Number: 2570 • 2017 ACR/ARHP Annual Meeting
The Functional Consequence of Human (hu)TLR8 on Macrophage Immunometabolism and Renal Inflammation in Murine Systemic Lupus Erythematosus
Naomi I. Maria¹, Megan Woods², Shani Martinez³, Weiqing Huang⁴ and Anne Davidson⁴, ¹Center for Autoimmune and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ²Center for Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ³Feinstein Institute for Medical Research, Manhasset, NY, ⁴Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Infiltrating macrophages are one of the hallmarks of renal inflammation and kidney damage in lupus nephritis. Increasing evidence suggests the crucial role of cell-specific…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].